Want to discover the best research that’s occurred this year? Editor, Martha Powell, highlights the best of 2018’s infectious diseases research in an A–Z.
Browsing: Research > Basic
Take a look behind the scenes of a recent Future Microbiology paper as we ask the authors about the challenges in treating respiratory tract infections and how nanomedicines could help.
New research has suggested that the spread of prions to the brain does not occur via the blood–brain barrier, implicating other mechanisms.
Positive results for zoliflodacin, EMA approval for fexinidazole and Merck cuts rotavirus commitment – take a look a the month’s industry headlines.
Scientists exploring the genome of Salmonella enterica Serovar Typhi have unveiled the alarming presence of antimicrobial resistance genes from isolates of the recent outbreak in Bangladesh; new geographical origins and spread of resistance is implicated.
Researchers from the University of Zurich have discovered that thanatin, a compound produced naturally by the spined soldier bug, could target Gram-negative bacteria by preventing formation of the bacteria’s outer membrane – an unprecedented mechanism.
New research has suggested that vaccinia viruses trick infected host cells into activating their cell movement mechanism, rapidly spreading the virus.
A Phase II, muti-center, randomized, open-label trial has reported that a novel oral antibiotic, zoliflodacin, is effective in the treatment of uncomplicated urogenital gonorrhea.
In this article, the authors discuss their research using non-ribosome targeting tobramycin-based adjuvants to overcome the intrinsic resistance observed in bacteria, Pseudomonas aeruginosa.
Collaborative research efforts with scientists from Janssen, the Scripps Research Institute, the University of Hong Kong, the University of Pennsylvania and more has led to success in creating a promising novel long-lasting llama-derived antibody therapy for influenza.